MEDCL logo

MedinCell S.A. Stock Price

ENXTPA:MEDCL Community·€908.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author
Create a narrative

MEDCL Share Price Performance

€27.44
11.76 (75.00%)
2.0% overvalued intrinsic discount
€26.90
Fair Value
€27.44
11.76 (75.00%)
2.0% overvalued intrinsic discount
€26.90
Fair Value
Price €27.44
AnalystConsensusTarget €26.90

MEDCL Community Narratives

AnalystConsensusTarget·
Fair Value €26.9 2.0% overvalued intrinsic discount

Global Expansion And Extended Patents Will Unlock Future Opportunities

2users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent MEDCL News & Updates

Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge

Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge

Global Expansion And Extended Patents Will Unlock Future Opportunities

Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.

News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts

Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts

MedinCell S.A. Key Details

€27.7m

Revenue

€0

Cost of Revenue

€27.7m

Gross Profit

€46.2m

Other Expenses

-€18.4m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Dec 09, 2025
Earnings per share (EPS)
-0.56
Gross Margin
100.00%
Net Profit Margin
-66.50%
Debt/Equity Ratio
-394.7%

MedinCell S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Exceptional growth potential and slightly overvalued.

1 Risk
2 Rewards
View Full Analysis

About MEDCL

Founded
2003
Employees
131
CEO
Christophe Douat
WebsiteView website
www.medincell.com

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

French Market Performance

  • 7 Days: -2.2%
  • 3 Months: 0.6%
  • 1 Year: 2.8%
  • Year to Date: 5.1%
Over the last 7 days, the market has dropped 2.2%, driven by a pullback of 3.0% in the Consumer Discretionary sector. In the last 12 months the market has been flat overall. Looking forward, earnings are forecast to grow by 12% annually. Market details ›